ILK-IN-2 (25-50 mg/kg, oral or intraperitoneal injection, once daily, 2-4 weeks) delays leukemia progression in mice and significantly improves the overall survival rate of mice harboring TCL1 leukemia cells[ 1 ].
ILK-IN-2 (25-50 mg/kg, orally, daily, for 35 days) inhibits the growth of PC-3 xenograft tumors in nude mice[2].
| Animal Model: | Pharmacokinetic properties of OSU-T315[1] |
| Dosage: | 50 mg/kg, daily for 4 weeks; 25 mg/kg, once daily for 2 weeks |
| Administration: | Oral; Intraperitoneal injection (i.p.) |
| Result: | Reduced white blood cell count and prolonged the survival of mice. |
| Animal Model: | PC-3 tumor xenograft mice model[2] |
| Dosage: | 25, 50 mg/kg; daily; 35 days |
| Administration: | Oral |
| Result: | Significantly inhibited tumor growth (25 and 50 mg/kg groups inhibited 48% and 62% respectively).
Showed that the phosphorylation of Ser-473-Akt was dose-dependently inhibited, while the phosphorylation of Thr-308-Akt was not affected. At the same time, the phosphorylation levels of GSK3β and MLC and the expression levels of YB-1, HER2 and EGFR also appeared in parallel decline.
|
![N-methyl-3-(1-(4-(piperazin-1-yl)phenyl)-5-(4'-(trifluoromethyl)-[1,1'-biphenyl]-4-yl)-1H-pyrazol-3-yl)propanamide Structure](/CAS/20180629/GIF/1333146-24-9.gif)
